Activation of pregnane X receptor (PXR) results in the induction of first-pass metabolism and drug efflux. Hereby, PXR may cause adverse drug reactions or therapeutic failure of drugs. PXR inhibition is thus an attractive option to minimise adverse effects or to improve therapeutic efficiencies; however, only a limited number of antagonists have been identified so far. We performed a cell-based high-throughput screen to identify PXR antagonists, using a library of approved and investigational drugs. Two approved drugs, pimecrolimus and pazopanib, emerged as novel potent antagonists of PXR activation, with IC50 values of 1.2 and 4.1 µM, respectively. We further characterised these with respect to receptor specificity, assembly of the PXR ligand-binding domain (LBD) and interactions with co-factors. In vitro and in silico assays were carried out to identify the site(s) of interaction with the PXR LBD. Primary human hepatocytes were used to investigate antagonism of the induction of endogenous PXR target genes. Pimecrolimus and pazopanib did not affect the transcriptional activity of other nuclear receptors. Both induced the release of co-repressor from PXR and likewise interfered with agonist-induced recruitment of co-activator. Cumulative evidence from cellular and in vitro assays, as well as molecular docking, suggested additional or exclusive binding outside the PXR ligand-binding pocket for both. The compounds differentially antagonised the induction of PXR-regulated genes by rifampicin in primary human hepatocytes. In conclusion, we here have identified two approved drugs as novel potent PXR inhibitors with differential receptor interaction profiles and gene selectivity in primary human hepatocytes.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Arnold KA, Eichelbaum M, Burk O (2004) Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor. Nucl Recept 2:1. https://doi.org/10.1186/1478-1336-2-1
Bitter A, Rümmele P, Klein K et al (2015) Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Arch Toxicol 89:2089–2103. https://doi.org/10.1007/s00204-014-1348-x
Boulin M, Guiu S, Chauffert B et al (2011) Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 22:741–748. https://doi.org/10.1097/CAD.0b013e328346a0c5
Bros M, Ross X-L, Pautz A et al (2003) The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. J Immunol 171:1825–1834. https://doi.org/10.4049/jimmunol.171.4.1825
Burk O, Tegude H, Koch I et al (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:2428–24288. https://doi.org/10.1074/jbc.M202345200
Burk O, Arnold KA, Nussler AK et al (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954–1965. https://doi.org/10.1124/mol.104.009019
Chai SC, Cherian MT, Wang Y-M, Chen T (2016) Small-molecule modulators of PXR and CAR. Biochim Biophys Acta 1859:1141–1154. https://doi.org/10.1016/j.bbagrm.2016.02.013
Chen T (2010) Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev 62:1257–1264. https://doi.org/10.1016/j.addr.2010.07.008
Chen Y, Tang Y, Robbins GT, Nie D (2010) Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 334:999–1008. https://doi.org/10.1124/jpet.110.168294
Chen Y, Tang Y, Guo C et al (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83:1112–1226. https://doi.org/10.1016/j.bcp.2012.01.030
Chrencik JE, Orans J, Moore LB et al (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125–1134. https://doi.org/10.1210/me.2004-0346
Das B, Madhukumar A, Anguiano J et al (2008) Synthesis of novel ketoconazole derivatives as inhibitors of the human pregnane X receptor (PXR; NR1I2; also termed SXR, PAR). Bioorg Med Chem Lett 15:3974–3977. https://doi.org/10.1016/j.bmcl.2008.06.018
Deng Y, Sychterz C, Suttle AB et al (2013) Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 43:443–453. https://doi.org/10.3109/00498254.2012.734642
Ekins S, Kholodovych V, Ai N et al (2008) Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 74:662–672. https://doi.org/10.1124/mol.108.049437
Elentner A, Ortner D, Clausen B et al (2015) Skin response to a carcinogen involve sthe xenobiotic receptor pregnane X receptor. Exp Dermatol 24:835–840. https://doi.org/10.1111/exd.12766
Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587. https://doi.org/10.1074/jbc.M010173200
Handschin C, Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55:649–673. https://doi.org/10.1124/pr.126.96.36.1999
Healan-Greenberg C, Waring J, Kempf D, Blomme EA, Tirona RG, Kim RB (2008) A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 36:500–507. https://doi.org/10.1124/dmd.107.019547
Hoffart E, Ghebreghiorghis L, Nussler AK et al (2012) Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor. Br J Pharmacol 165:1595–1608. https://doi.org/10.1111/j.1476-5381.2011.01665.x
Huang H, Wang H, Sinz M et al (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268. https://doi.org/10.1038/sj.onc.1209788
Hustert E, Zibat A, Presecan-Siedel E et al (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454–1459
Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL (2006) A comparison of assay performance measures in screening assays: signal window, Z′ factor, and assay variability ratio. J Biomol Screen 11:247–252. https://doi.org/10.1177/1087057105285610
Jeske J, Windshugel B, Thasler WE, Schwab M, Burk O (2017) Human pregnane X receptor is activated by dibenzazepine carbamate-based inhibitors of constitutive androstane receptor. Arch Toxicol. https://doi.org/10.1007/s00204-017-1948-3
Kandel BA, Thomas M, Winter S et al (2016) Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes. Biochim Biophys Acta 1859:1218–1227. https://doi.org/10.1016/j.bbagrm.2016.03.007
Krausova L, Stejskalova L, Wang H et al (2011) Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem Pharmacol 1:1771–1780. https://doi.org/10.1016/j.bcp.2011.08.023
Lee SM, Schelcher C, Demmel M et al (2013) Isolation of human hepatocytes by a two-step collagenase perfusion procedure. J Vis Exp. https://doi.org/10.3791/50615
Lemaire G, Benod C, Nahoum V et al (2007) Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to “in vivo” biological activity. Mol Pharmacol 72:572–581. https://doi.org/10.1124/mol.106.033415
Lim Y-P, Ma C-Y, Liu C-L et al (2012) Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid Based Complement Alternat Med 2012:242810. https://doi.org/10.1155/2012/242810
Lin W, Wang YM, Chai SC et al (2017) SPA70 is a potent antagonist of human pregnane X receptor. Nat Commun 8:741. https://doi.org/10.1038/s41467-017-00780-5
Liu C-L, Lim Y-P, Hu M-L (2012) Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 10:242–257. https://doi.org/10.3390/md10010242
Moore TW, Mayne CG, Katzenellenbogen JA (2010) Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 24:683–695. https://doi.org/10.1210/me.2009-0362
Piedade R, Traub S, Bitter A et al (2015) Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor. Antimicrob Agents Chemother 59:96–104. https://doi.org/10.1128/AAC.04140-14
Pissios P, Tzameli I, Kushner P, Moore DD (2000) Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol Cell 6:245–253 pii]
Ratajewski M, Grzelak I, Wiśniewska K et al (2015) Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett 232:193–202. https://doi.org/10.1016/j.toxlet.2014.10.009
Riedmaier S, Klein K, Hofmann U et al (2010) UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65–73. https://doi.org/10.1038/clpt.2009.181
Sinz M, Kim S, Zhu Z et al (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–388
Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590. https://doi.org/10.1038/87912
Tabb MM, Kholodovych V, Grün F et al (2004) Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect 112:163–169
Takeshita A, Taguchi M, Koibuchi N, Ozawa Y (2002) Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277:32453–32458. https://doi.org/10.1074/jbc.M111245200
Thasler WE, Weiss TS, Schillhorn K et al (2003) Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4:49–56. https://doi.org/10.1023/A:1026392429112
Tice CM, Zheng Y-J (2016) Non-canonical modulators of nuclear receptors. Bioorg Med Chem Lett 26:2157–2164. https://doi.org/10.1016/j.bmcl.2016.07.067
Tolson AH, Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62:1238–1249. https://doi.org/10.1016/j.addr.2010.08.006
van Geel RM, Beijnen JH, Schellens JH (2012) Concise drug review: pazopanib and axitinib. Oncologist 17:1081–1089. https://doi.org/10.1634/theoncologist.2012-0055
Venkatesh M, Wang H, Cayer J et al (2011) In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol 80:124–135. https://doi.org/10.1124/mol.111.071787
Wang H, Faucette S, Sueyoshi T et al (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146–14152. https://doi.org/10.1074/jbc.M212482200
Wang H, Huang H, Li H et al (2007) Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 13:2488–2495. https://doi.org/10.1158/1078-0432.CCR-06-1592
Wang H, Li H, Moore LB et al (2008) The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 22:838–857. https://doi.org/10.1210/me.2007-0218
Wang H, Venkatesh M, Li H et al (2011) Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest 121:3220–3232. https://doi.org/10.1172/JCI41514
Wang YM, Ong SS, Chai SC, Chen T (2012) Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol 8:803–817. https://doi.org/10.1517/17425255.2012.685237
Zhang J, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73. https://doi.org/10.1177/108705719900400206
Zhou C, Poulton E-J, Grün F et al (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229. https://doi.org/10.1124/mol.106.029264
Zhu Z, Kim S, Chen T et al (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533–540. https://doi.org/10.1177/1087057104264902
Zhuo W, Hu L, Lv J et al (2014) Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol 74:217–227. https://doi.org/10.1007/s00280-014-2494-9
Zollinger M, Waldmeier F, Hartmann S et al (2006) Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos 34:765–774. https://doi.org/10.1124/dmd.105.007732
We appreciate the expert technical assistance of K. Abuazi-Rincones. The non-profit foundation Human Tissue and Cell Research (Regensburg, Germany), which holds human tissue on trust, making it broadly available for research on an ethical and legal basis, kindly provided liver tissue for the preparation of human primary hepatocytes. Primary human hepatocytes were kindly prepared by M. Demmel (Hepacult GmbH, München, Germany). This work was supported by the São Paulo state funding agency FAPESP (Grants 2014/03644-9, 2014/27313-1) and CNPq-DAAD Science Without Borders programme (T.K.), by the Robert Bosch Foundation, Stuttgart, Germany (O.B., M.S.), the Horizon 2020-PHC-2015 Grant U-PGx 668353 (M.S.) and by the Interfaculty Center for Pharmacogenomics and Pharma Research of the University of Tübingen, Germany (O.B., J.J.).
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Human and animal rights statement
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Burk, O., Kuzikov, M., Kronenberger, T. et al. Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol 92, 1435–1451 (2018). https://doi.org/10.1007/s00204-018-2165-4
- Pregnane X Receptor
- High-throughput screening